E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
recurrent or metastatic cervical cancer |
carcinoma della cervice ricorrente o metastatico |
|
E.1.1.1 | Medical condition in easily understood language |
recurrent or metastatic cervical cancer |
carcinoma della cervice ricorrente o metastatico |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008342 |
E.1.2 | Term | Cervix carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Determine the anti-tumor efficacy in patients with cervical cancer |
Determinare l'efficacia antitumorale in pazienti con carcinoma della cervice |
|
E.2.2 | Secondary objectives of the trial |
• Evaluate durability
• Evaluate other clinical outcomes
• Assess safety and tolerability
|
Valutare la durata
Valutare altri esiti clinici
Valutare la sicurezza e la tollerabilità |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology, that:
1. Have experienced disease progression during or after treatment with:
- Paclitaxel+cisplatin or carboplatin OR
- Paclitaxel+topotecan,
in combination with bevacizumab unless patients are ineligible for bevacizumab treatment according to local standards.
2. Have received no more than 2 prior systemic treatment regimens for recurrent or metastatic cervical cancer. Chemotherapy administered in combination with radiation therapy is not considered a prior systemic regimen.
3. Are not candidates for curative therapy, including but not limited to, radiotherapy or exenterative surgery.
• Age ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Life expectancy of at least three months
• A negative serum pregnancy test for patients of reproductive potential
• Patients of reproductive potential must agree to use adequate contraception during and for 6 months after the last IMP administration
• Following receipt of verbal and written information about the trial, patients must provide signed informed consent before any trial-related activity is carried out
• Acceptable coagulation status:
o International normalized ratio (INR) ≤ 1.2 (without anti-coagulation therapy).
o Activated partial thromboplastin time (aPTT) ≤ 1.25 ULN.
o Patients on anti-coagulation therapy (e.g., warfarin) must be on a steady dose (no active titration) for at least 4 weeks prior to screening and must have an INR ≤ 2.5 for eligibility. Concurrent use of prophylactic AcetylSalicylic Acid (ASA, e.g., aspirin) for patients on anti-coagulation therapy (e.g., warfarin) is prohibited. |
•Pazienti con carcinoma della cervice extra-pelvico metastatico o recidivante, compresi quelli a istologia squamocellulare, di adenocarcinoma o adenosquamosa, che:
1. Abbiano manifestato progressione della malattia durante o dopo il trattamento con:
-paclitaxel + cisplatino o carboplatino
OPPURE
-paclitaxel + topotecan,
in combinazione con bevacizumab, salvo che le pazienti non siano idonee al trattamento con bevacizumab secondo gli standard locali.
2. Abbiano ricevuto non più di 2 precedenti regimi terapeutici sistemici per il carcinoma della cervice recidivante o metastatico. La chemioterapia somministrata in combinazione con la radioterapia non è considerata un precedente regime sistemico.
3. Non siano candidate per la terapia curativa, compresa, senza limitazione, la radioterapia o chirurgia exenterativa.
•Età ≥18 anni.
•Stato di validità secondo il Gruppo cooperativo orientale di oncologia (ECOG) pari a 0 o 1
•Aspettativa di vita di almeno tre mesi.
•Negatività al test di gravidanza su siero per le pazienti in età fertile.
•Le pazienti in età fertile devono acconsentire all’uso di contraccezione adeguata durante e per 6 mesi dopo l’ultima somministrazione dell’IMP.
•Una volta ricevute informazioni verbali e scritte sulla sperimentazione, le pazienti devono fornire il consenso informato scritto prima di sottoporsi a qualsiasi attività correlata alla sperimentazione.
•Stato di coagulazione accettabile:
o International normalized ratio (INR) ≤ 1.2 (senza anti-coagulazione terapia).
•Tempo di tromboplastina parziale attivato (aPTT) ≤ 1,25 ULN.
•Le pazienti in terapia anticoagulante (ad es. Warfarin) devono essere su una dose costante (nessuna titolazione attiva) per almeno 4 settimane prima dello screening e devono avere un INR ≤ 2.5 per essere considerate idonee. Uso concomitante di acido acetilsalicilico profilattico (ASA, ad es., aspirina) per pazienti in terapia anticoagulante la terapia (ad es. warfarin) è proibita. |
|
E.4 | Principal exclusion criteria |
• Known past or current coagulation defects
• Ongoing major bleeding
• Clinically significant cardiac disease
• Other cancer: Known past or current malignancy other than inclusion diagnosis
|
• Difetti di coagulazione noti pregressi o attuali
• sanguinamento maggiore in corso
• Malattia cardiaca clinicamente significativa
• Altri tumori: tumore maligno noto pregresso o attuale che non rientri nella diagnosi di inclusione
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Confirmed objective response rate based upon RECIST v1.1 assessed by the independent review committee |
Tasso di risposta obiettiva confermato in base alla versione 1.1 dei Criteri di valutazione della risposta nei tumori solidi (RECIST), valutato da un comitato di revisione indipendente |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• During the trial, see protocol |
durante lo studio, fare riferimento al protocollo |
|
E.5.2 | Secondary end point(s) |
• Duration of response (DOR) based upon RECIST v1.1
• Confirmed objective response rate based upon RECIST v1.1 assessed by the investigator
• Time to response based upon RECIST v1.1
• Progression free survival based upon RECIST v1.1
• Overall survival
• Adverse events and safety laboratory parameters
• Pharmacokinetics (PK)
• Immunogenicity
|
• Durata della risposta (DOR) in base ai criteri RECIST v1.1
• Tasso di risposta obiettiva confermato valutato dallo sperimentatore in base ai criteri RECIST v1.1
• Tempo alla risposta in base ai criteri RECIST v1.1
• Sopravvivenza libera da progressione in base ai criteri RECIST v1.1
• Sopravvivenza complessiva
• Eventi avversi e parametri di laboratorio di sicurezza.
• Farmacocinetica (PK)
• Immunogenicità
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• During the trial, see protocol |
durante lo studio, fare riferimento al protocollo |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 33 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Czech Republic |
Denmark |
Germany |
Italy |
Spain |
Sweden |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |